Last reviewed · How we verify
Fat degeneration of supraspinatus muscle — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Fat degeneration of supraspinatus muscle (Fat degeneration of supraspinatus muscle) — Applied Biologics, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fat degeneration of supraspinatus muscle TARGET | Fat degeneration of supraspinatus muscle | Applied Biologics, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fat degeneration of supraspinatus muscle CI watch — RSS
- Fat degeneration of supraspinatus muscle CI watch — Atom
- Fat degeneration of supraspinatus muscle CI watch — JSON
- Fat degeneration of supraspinatus muscle alone — RSS
Cite this brief
Drug Landscape (2026). Fat degeneration of supraspinatus muscle — Competitive Intelligence Brief. https://druglandscape.com/ci/fat-degeneration-of-supraspinatus-muscle. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab